MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

← catalyst calendar

NCT06549751 · readout in 697 d

Sponsored by Marker Therapeutics, Inc. (industry) · MRKR — their whole pipeline →. With M.D. Anderson Cancer Center.

Phase

Phase 1

Status

Not yet recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

38estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-16

estimated

When the study began enrolling

Primary completion

2028-07-16

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-09-16

estimated

The whole study's end, after follow-up

First posted

2024-08-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Pancreas Cancer
Pancreatic Cancer Metastatic
Pancreatic Cancer (Unresectable)

Interventions

Drug: MT-601 dose 200 million cells
Drug: MT-601 dose 400 million cells
Drug: MT-601 dose 800 million cells
Drug: MT-601 dose 1200 million cells

Primary outcome

what the primary-completion date above is the date OF

During Dose Escalation - determine the MTD, recommended expansion dose, or MPD of MT-601 administered during maintenance capacitabine following treatment with FOLFIRINOX (FFX) or NALIRIFOX (NLX).

measured Through study completion. Approximately 24 months

Permalink · MRKR's whole pipeline · Catalyst calendar · Every registered study · What changed